LEGN - NASDAQ
Legend Biotech Corporation
$35.98
+3.1%Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
At a Glance
Live SnapshotSEC Filings
LEGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
6-K 6-K 2026 Q2 Q2 | June 02, 2026 | June 02, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | June 01, 2026 | June 01, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | May 21, 2026 | May 21, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
6-K 6-K 2026 Q2 Q2 | April 14, 2026 | April 14, 2026 | 2026 | |
20-F 20-F 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
6-K 6-K 2026 Q1 Q1 | March 10, 2026 | March 10, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | February 06, 2026 | February 06, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | January 23, 2026 | January 23, 2026 | 2026 | |
6-K 6-K 2026 Q1 Q1 | January 21, 2026 | January 21, 2026 | 2026 |
Understanding SEC Filings
Essential regulatory documents for investors
SEC filings are mandatory documents that publicly traded companies must submit to the Securities and Exchange Commission. These reports provide critical insights into a company's financial health, operations, risks, and strategic direction. For investors conducting due diligence, these filings are the most authoritative source of company information.
Annual Report
Comprehensive annual financial report filed within 60-90 days of fiscal year-end. Includes audited financial statements, management discussion & analysis (MD&A), risk factors, and detailed business operations. The most thorough financial disclosure of the year.
Quarterly Report
Unaudited quarterly financial report filed within 40-45 days after each of the first three fiscal quarters. Provides updates on financial position, results of operations, and significant events. Essential for tracking quarterly performance trends.
Current Report
Event-driven filing for material events that shareholders should know about, filed within 4 business days. Includes acquisitions, executive changes, bankruptcy, earnings releases, and other significant developments. Critical for staying informed about breaking news.
Proxy Statement
Definitive proxy statement sent to shareholders before annual meetings. Contains executive compensation details, board member information, voting matters, and corporate governance policies. Key for understanding management incentives and board composition.
Registration Statement
Initial registration for securities offerings, including IPOs. Provides detailed company history, business model, financial statements, risk factors, and use of proceeds. Essential for evaluating new investment opportunities and understanding company fundamentals.
Foreign Annual Report
Annual report for foreign private issuers, equivalent to Form 10-K for non-U.S. companies. Filed within 4-6 months of fiscal year-end. Contains audited financials, business description, and regulatory disclosures adapted for international companies.
Why SEC Filings Matter
- Regulatory Accuracy: Filings are subject to SEC review and legal penalties for misstatements, ensuring high data quality
- Management Insights: MD&A sections reveal management's perspective on trends, challenges, and future outlook
- Risk Assessment: Detailed risk factor disclosures help investors understand potential threats to business operations
- Competitive Analysis: Business descriptions and segment data enable comparison with industry peers
- Historical Context: Years of filings provide trend analysis and context for current performance
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.